LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Happy Easter to all you warriors! While waiting for the AACR 2026 meeting, another update with interesting clinical and preclinical studies. Have a fantastic Easter! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen […]
Prostate cancer becomes especially hard to treat when it turns resistant to hormone therapies like enzalutamide, largely because of a protein complex called PRC2 that shuts down genes needed to fight tumors. PRC2’s key parts, EZH2 and EED, fuel cancer growth, immune evasion, and drug resistance in prostate tumors, as well as others like endometrial […]
PSMA-targeted T-cell engagers have struggled in solid tumors because they don’t activate T cells strongly enough and the immune cells become exhausted quickly. QL535 solves this problem by adding a second co-stimulatory signal through CD2, a molecule on T cells that’s abundant in prostate cancer tumors. Researchers analyzed immune cells from 14 advanced prostate cancer […]
LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. […]
The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]
Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]
A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]
Xaluritamig (AMG 509) represents a promising new immunotherapy option for men with metastatic castration-resistant prostate cancer, or mCRPC, through this new Phase 1 trial. The study aims to evaluate the safety profile of xaluritamig administered as monotherapy (plus ADT, as usual) at a specific proposed regimen in adult male participants whose cancer has progressed despite […]
MRT‑2359 is an investigational, orally bioavailable molecular‑glue degrader targeting GSPT1, a protein involved in translation termination. We talked about this new molecule in this article just one month ago, we already have some good news. In prostate cancer it is being studied in combination with androgen‑receptor (AR)‑axis inhibitors, particularly in metastatic castration‑resistant prostate cancer (mCRPC), […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This edition of the newsletter will also be mainly focused on preclinical studies that are approaching human trials. The AACR 2026 meeting begins in about twenty days, and updates on ongoing clinical trials will not be available until just […]